📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of otcs and supplements ii/2025 { "detected_language": "romanian", "translated_text": "lot-0001, title: antinevralgic p ® equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0002, title: bisacodil sintofarm 10 mg ®, dulcolax 10 mg ®, laxamag 10 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0003, title: canespor ®, biazol ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0004, title: sapromed cutaneous powder ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0005, title: oximed ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0007, title: bepanthen ®, dexpanthenol ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0010, title: magne b6 sanofi ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0014, title: codamin p ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0015, title: betadine 30 ml®, iodine ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0016, title: rowathinex cps® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0017, title: lagosa ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0018, title: espumisan 100 mg drops ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0020, title: gaviscon menthol oral suspension ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under estimated value excluding vat: 20792.00 ron.Centralized framework agreement for 24 months for the supply of otcs and supplements ii/2025